WASHINGTON, March 27 (Reuters) - It is difficult to tell how well brain cancer patients responded to Genentech Inc’s cancer drug Avastin in early studies from the company, U.S. Food and Drug Administration staff said in documents released on Friday.
WASHINGTON, March 27 (Reuters) - It is difficult to tell how well brain cancer patients responded to Genentech Inc’s cancer drug Avastin in early studies from the company, U.S. Food and Drug Administration staff said in documents released on Friday.
